m6A甲基化修饰非编码RNA调控病理性心脏重塑的作用

Regulation of N6-methyladenosine on non-coding RNAs in pathological cardiac remodeling

背景:m6A甲基化修饰非编码RNA是病理性心脏重塑形成机制的研究热点,在心血管疾病的发生发展中起着重要作用。目的:总结m6A甲基化修饰非编码RNA对调控病理性心肌肥大、心肌细胞死亡、心肌纤维化与血管重塑等病理性心脏重塑主要过程的可能作用机制。方法:以“m6A甲基化修饰,非编码RNA,病理性心肌肥大,心肌细胞凋亡,心肌细胞焦亡,心肌细胞铁死亡,心肌纤维化,血管重塑”为中文主题词,以“m6A、non-coding RNA,pathological cardiac hypertrophy,cardiomyocyte apoptosis,cardiomyocyte pyroptosis,cardiomyocyte ferroptosis,myocardial fibrosis,vascular remodeling”为英文主题词,检索中国知网、PubMed、Web of Science数据库1974年1月至2023年4月发表的相关文献,对符合筛选标准的86篇文献进行综述。结果与结论:①m6A甲基化修饰是一种动态可逆的表观遗传修饰方式;②病理性心脏重塑主要包括病理性心肌肥大、心肌细胞死亡、心肌纤维化、血管重塑,m6A相关酶可调控病理性心脏重塑相关进程;③m6A甲基化修饰相关酶可通过多种非编码RNA与不同信号通路参与调控病理性心脏重塑过程,可作为心血管疾病新的潜在干预方式;④在病理性心脏重塑中,m6A甲基化修饰与非编码RNA之间的调控关系仍处于起步阶段,随着表观遗传学的发展,m6A甲基化修饰非编码RNA来调控病理性心脏重塑有望有新的发展。

BACKGROUND:N6-methyladenosine(m6A)is a hot research topic in the mechanism of pathological cardiac remodeling and plays an important role in the development of cardiovascular diseases.OBJECTIVE:To summarize the possible mechanism by which m6A modification in non-coding RNAs regulates the main processes of pathological cardiac remodeling,such as pathological cardiac hypertrophy,cardiomyocyte death,myocardial fibrosis and vascular remodeling.METHODS:“m6A,non-coding RNA,pathological cardiac hypertrophy,cardiomyocyte apoptosis,cardiomyocyte pyroptosis,cardiomyocyte ferroptosis,myocardial fibrosis,vascular remodeling”were used as search terms in Chinese and English.Relevant literature from CNKI,PubMed and Web of Science databases published from January 1974 to April 2023 was retrieved,and finally 86 eligible articles were reviewed.RESULTS AND CONCLUSION:m6A modification is a highly dynamic and reversible modification.Pathological cardiac remodeling mainly involves pathological cardiac hypertrophy,cardiomyocyte apoptosis,cardiomyocyte pyroptosis,cardiomyocyte ferroptosis,myocardial fibrosis and vascular remodeling.m6A-related enzymes can regulate pathological cardiac remodeling processes through various non-coding RNAs and different signaling pathways,which can be used as a new potential intervention for cardiovascular diseases.In pathological cardiac remodeling,research on the regulatory relationship between m6A modification and non-coding RNAs is still in its infancy.With the development of epigenetics,m6A modification in non-coding RNAs is expected to have a new development in the regulation of pathological cardiac remodeling.